Cargando…

Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial

BACKGROUND: Initiation and titration of human regular U-500 insulin (U-500R) with a dosing algorithm of either thrice daily (TID) or twice daily (BID) improved glycemic control with fewer injections in patients with type 2 diabetes treated with high-dose, high-volume U-100 insulin. The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kabul, Samaneh, Hood, Robert C., Duan, Ran, DeLozier, Amy M., Settles, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045589/ https://www.ncbi.nlm.nih.gov/pubmed/27716283 http://dx.doi.org/10.1186/s12955-016-0541-4

Ejemplares similares

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
por: de la Peña, Amparo, et al.
Publicado: (2011)

Delayed Response to U-500 Regular Insulin
por: Davidson, Mayer B.
Publicado: (2018)

Insulin Edema With Use of U-500 Regular Insulin in a Hybrid Closed-Loop Insulin Pump
por: Vasigh, Mostafa, et al.
Publicado: (2020)

MON-152 Less Is More: Human Regular U-500 Insulin
por: Lugo Lopez, Zahira, et al.
Publicado: (2019)

U-500 Regular Insulin: Clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients
por: Davidson, Mayer B., et al.
Publicado: (2010)

FRI654 Concentrated Regular U-500 Insulin In An Automated Insulin Delivery System: A Case Report
por: Aurora, John, et al.
Publicado: (2023)

SAT167 Risk Of Life Threatening Hypoglycemia When Using U-100 Insulin Syringes To Administer R U-500 Insulin
por: Rizwan, Tehlil, et al.
Publicado: (2023)

Duration and onset of action of high dose U‐500 regular insulin in severely insulin resistant subjects with type 2 diabetes
por: Shrestha, Rupendra T., et al.
Publicado: (2018)

LBSUN294 Insulin-induced Abdominal Acanthosis Nigricans From High Doses Of Insulin U-500
por: Yap, Sara Elizabeth, et al.
Publicado: (2022)

Development and Implementation of a U-500 Regular Insulin Program in a Federally Qualified Health Center
por: Shaw, Kathy F., et al.
Publicado: (2017)

Advancing Patient Safety and Access to Concentrated Insulin (U-500 Regular Insulin) in the Veterans Health Administration: A Clinician Education Program in the Primary Care Setting
por: Lutz-McCain, Stacey J., et al.
Publicado: (2018)

Initiation of human regular U-500 insulin use is associated with improved glycemic control: a real-world US cohort study
por: Eby, Elizabeth L, et al.
Publicado: (2015)

OR30-02 Efficacy and Safety Comparison Between U100 Regular Human Insulin and U100 Rapid Acting Insulin When Delivered by a 24 Hour Wearable Insulin Delivery Device in Type 2 Diabetes
por: Mora, Pablo, et al.
Publicado: (2020)

Treatment Patterns and Outcomes Before and After Humulin R U-500 Initiation Among US Patients with Type 2 Diabetes Previously Prescribed ≤ 200 Units/day of U-100 Insulin
por: Chen, Jieling, et al.
Publicado: (2022)

Patient‐reported outcomes in a study of human regular U‐500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes
por: Chen, Jieling, et al.
Publicado: (2020)

Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study
por: Grunberger, George, et al.
Publicado: (2020)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

SAT-LB028 Efficacy and Safety of Pramlintide as an Adjunct to Insulin U500 Therapy in Veterans with Severe Insulin Resistance
por: Oprea, Mihaela, et al.
Publicado: (2019)

Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study
por: Duque, Natalia, et al.
Publicado: (2021)

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
por: de la Peña, Amparo, et al.
Publicado: (2015)

Efficacy, safety and cost-effectiveness comparison between U-100 human regular insulin and rapid acting insulin when delivered by V-Go wearable insulin delivery device in type 2 diabetes
por: Mora, Pablo F, et al.
Publicado: (2020)

Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes
por: Granata, Joseph A., et al.
Publicado: (2015)

Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial
por: Vrebalov Cindro, Pavle, et al.
Publicado: (2022)

In Silico Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 Diabetes
por: Schiavon, Michele, et al.
Publicado: (2020)

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D
por: Manjunath, Aparna, et al.
Publicado: (2022)

Erratum: Delayed Response to U-500 Regular Insulin. Clinical Diabetes 2018;36: 77–79 (DOI: 10.2337/cd16-0058)
por: Davidson, Mayer B.
Publicado: (2018)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia
por: Lalić, Nebojša, et al.
Publicado: (2018)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D
por: Kunder, Sushil, et al.
Publicado: (2022)

U500 Disposable Patch Insulin Pump: Results and Discussion of a Veterans Affairs Pilot Study
por: Martin, Christopher, et al.
Publicado: (2018)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
por: Kumar, Ajay, et al.
Publicado: (2016)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Evaluation of a Conservative Pharmacist-led U-500R Insulin Management Protocol in the Primary Care Setting
por: Dumont, Cyndi, et al.
Publicado: (2020)

Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
por: Kovatchev, Boris, et al.
Publicado: (2020)

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
por: Chaykin, Louis, et al.
Publicado: (2019)

Prolonged hyperinsulinemia after subcutaneous injection of 2400 U regular insulin in a suicide attempt: Time course of serum insulin with frequent measurements
por: Hiromine, Yoshihisa, et al.
Publicado: (2012)

Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial
por: Ji, Linong, et al.
Publicado: (2019)

Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
por: Gourdy, Pierre, et al.
Publicado: (2019)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
por: Russel-Szymczyk, Monika, et al.
Publicado: (2019)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_50lku4sfau5argdcrrbmohd6b0